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Abstract: Resistance to checkpoint-blockade treatments is a challenge in the clinic. Both primary
and acquired resistance have become major obstacles, greatly limiting the long-lasting effects and
wide application of blockade therapy. Many patients with metastatic melanoma eventually require
further therapy. The absence of T-cell infiltration to the tumor site is a well-accepted contributor
limiting immune checkpoint inhibitor efficacy. In this study, we combined intratumoral injection of
plasmid IL-12 with electrotransfer and anti-PD-1 in metastatic B16F10 melanoma tumor model to
increase tumor-infiltrating lymphocytes and improve therapeutic efficacy. We showed that effective
anti-tumor responses required a subset of tumor-infiltrating CD8+ and CD4+ T cells. Additionally,
the combination therapy induced higher MHC-I surface expression on tumor cells to hamper tumor
cells escaping from immune recognition. Furthermore, we found that activating T cells by exposure
to IL-12 resulted in tumors sensitized to anti-PD-1 treatment, suggesting a therapeutic strategy to
improve responses to checkpoint blockade.
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1. Introduction
The immune system is a key player in cancer development and progression. The interaction between the tumor and surrounding immune cells is constant and complex, leading
either to the inhibition or stimulation of tumor growth. The role of the immune system in
the rejection of solid tumors has been well demonstrated in both carcinogen-induced and
spontaneous experimental tumor models [1]. The immune-mediated eradication of established tumors depends on several factors, including the presence of tumor antigen-primed
CD8+ effector T cells, the ability of such T cells to traffic to sites of tumor growth, the persistence of cells in sufficient concentrations at the tumor site, and the capacity of the T cells to
maintain cytotoxic effector functions in the face of local immunosuppressive mechanisms.
Immunotherapy has revolutionized cancer therapy. The suppression of tumor growth can
be achieved via increasing tumor-infiltrating lymphocytes, such as CD8+ T cells [2]. A lack
of T cells in tumors can lead to resistance to immunotherapy. Thus, strategies aimed at
maintaining effector T cells within the tumor microenvironment following exposure to
specific cytokines, i.e., IL-12, combined with anti-PD1, are a high priority [3,4].
Immune checkpoint inhibitors, such as antibodies against PD-1, would be a prioritized
therapeutic modality when CD8+ T cells with a high expression of PD-1 are present in the
tumor milieu. This approach has been demonstrated to be effective against a large number
of cancer types, including melanoma, non-small-cell lung cancer, and renal cancer [5,6]. In
addition, checkpoint inhibitors, such as anti-PD1, have recently been shown to substantially
extend survival in melanoma patients [7,8]. Despite significant clinical benefits, a high
number of cancer patients relapse within a few months after initiation of therapy [9–12]. The
prognosis of melanoma remains poor, especially when the disease also involves mucosal
surfaces [13]. A limited number of tumor-infiltrating immune cells might be one of the
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mechanisms leading to resistance to PD1 inhibition in patients [14]. Evidence from clinical
cases demonstrated that a large proportion of solid cancers appeared immune privileged
to lymphocytic infiltrate or were non-immunogenic (immunologically “cold”) and thus
protected from cytotoxic attack by T lymphocytes [15]. In patients who resist immune
checkpoint blockades, CD8+ T cells localize peritumorally, whereas they accumulate in
the tumor mass in patients who respond to immune checkpoint blockade, suggesting that
strategies aimed at promoting T-cell infiltration into the tumor mass are indispensable for
the induction of therapeutic immunity [16,17]. Given that the function of some cytokines
is recruiting and cueing the proliferation of lymphocytes to bolster the immune response,
combining checkpoint blockade with cytokines might improve response rates [18–20].
Prior studies in our lab suggest that the local expression of plasmid-encoding IL-12 (pIL12) delivered by gene electrotransfer (GET) has the function of increasing immune cell
infiltration into the tumor microenvironment [4].
The trigger of an anti-tumor immune response starts with major histocompatibility
complex class I (MHC-I) and II (MHC-II) presenting tumor antigens to CD8+ and CD4+
T cells, respectively. That is, MHC molecules play a pivotal role in the initiation and
subsequent anti-tumor immune response [21,22]. However, evidence from clinical cases
demonstrates that a large proportion of solid cancers appear to down-regulate or lose MHCI antigen presentation [21,23,24]. We previously demonstrated that the intra-tumor delivery
of plasmid IL-12 with GET resulted in a highly efficient anti-tumor response [25–27]. Herein,
we expanded upon our previous findings to demonstrate that pIL-12 GET combined with
anti-PD1 in metastatic melanoma tumor model could shift poorly immunogenic tumors
milieu into highly inflamed immunologically active lesions. One mechanism behind this
observation is an increase in MHC-I surface expression on tumor cells, thus, converting
tumor cells into antigen-presenting cells combined with IL-12 working to recruit tumorinfiltrating lymphocytes leading to the eradication of established tumors and generating
tumor-specific memory.
2. Materials and Methods
2.1. Cells
B16F10 murine melanoma cells (American Type Culture Collection) were maintained
in Dulbecco’s Modified Eagle Medium supplemented with 10% FCS and 100 units/mL of
penicillin and 100 µg/mL of streptomycin. B16F10-Red-FLuc cells (PerkinElmer, Waltham,
MA, USA) were cultured in RPMI 1640 supplemented with 10% FCS.
In vitro electroporation was performed as follows: B16F10 cells (107 /mL) were treated
with electric pulses (six 500 V/cm, 5 ms pulses with 1.0 s interval) in a 2 mm cuvette with
or without plasmid DNA (20 µg) and allowed to grow for 24 h, 48 h or 72 h. The cells
were then assessed by flow cytometry for the expression of H-2Kb and PDL1. B16F10 cells
at proper confluency were subsequently treated with recombinant mouse IFN-γ or IL-12
(Biolegend, San Diego, CA, USA) at various concentrations as control. Additional analysis
was performed using FlowJo software V10 (Tree Star, Inc., San Carlos, CA, USA).
2.2. Animals and Tumor Models
Female C57BL/6 mice (6–8 weeks) were obtained from Jackson Laboratories. 1 × 106
B16F10 cells were injected on the left flank (subcutaneous, (s.c.) to establish a primary
tumor. Seven days after s.c. injection (Day 0), mice were injected intraperitoneal (i.p.) with
5 × 104 B16F10-Red-FLuc cells to establish peritoneal metastases.
Metastatic spread within the peritoneal cavity was assessed using IVIS® Lumina
III in vivo imaging system (IVIS, PerkinElmer, USA) on day 1 and followed every 5 to
10 days thereafter. The anesthetized animals received 15 mg/kg D-luciferin (200 µL/mouse,
PerkinElmer, USA) via intraperitoneal injection. Luciferase intensity in the peritoneal
cavity exceeding background levels (4~5 × 104 photons/s) was used for the confirmation of
tumor growth.
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Established subcutaneous tumors (40–60 mm3 ) were treated on days 0, 4, and 7 via
intratumoral injection of plasmid encoding mouse pUCMV3-mIL-12 (pIL-12, 50 µg/50µL,
Aldevron, Fargo, ND), with GET (ten 600 V/cm, 5 ms pulses with a non-penetrating caliper
electrodes with an adjustable distance between electrodes) after anesthetization. The antiPD-1 (RMP1-14, BioXCell, Lebanon, NH) was injected i.p. at a dose of 200 µg/100 µL on
days 0, 4, 7, and 14. The mice were observed every 3 to 5 days, which included tumor
measurements, weight, and health status. Tumor volume was calculated using the formula
v = 0.52 × length × width2 . When rechallenged, the mice were injected with 5 × 105 B16F10
cells in the right flank.
For depletion experiments in vivo, the mice were treated with depletion antibodies
at a dose of 200 ug/100 µL (i.p., anti-CD4 (clone GK1.5, BioXCell), anti-CD8 (clone 2.43,
BioXCell), anti-IFN-γ (XMG1.2, BioXcell) and anti-NK1.1 (clone PK136, BioXCell)) on day
−1, 1, 4, 7, 12, and 17. The cellular depletions of CD8+ T cells, CD4+ T cells, and NK cells
were confirmed by flow cytometry of PBMC. The level of depletion was 98% for both T-cell
subsets (Figure S3A–E).
2.3. Tissue Preparation
The blood was collected from the lateral tail vein at specified time points in tubes
containing ethylenediaminetetraacetic acid (EDTA) anticoagulant in order to obtain the
plasma. The plasma was stored at −20 degrees for ELISA, and the cells were analyzed by
flow cytometry.
The trimmed tumor tissues were fixed in Zinc Fixative (BD Bioscience, Franklin
Lakes, NJ, USA), followed by dehydrated and embedded in paraffin in preparation for
immunohistochemistry (IHC).
Single cells were isolated from the spleen using a cell strainer (40 µm) followed by
treatment with Ammonium-Chloride-Potassium (ACK, A1049201, Altham, MA, USA) to
lyse mouse erythrocytes. For tumor-infiltrating lymphocytes (TILs), the tumor tissues were
dissociated into single-cell suspensions using the GentleMACS Dissociator (Miltenyi Biotec,
Gaithersburg, MD, USA) according to the manufacturer’s instructions. TILs were enriched
with 75% Ficoll-Paque premium (GE Healthcare Bio-Science AB, Chicago, IL, USA).
For tumor homogenization, the tissues were snap-frozen in liquid nitrogen and
lyophilized overnight, homogenized with GentleMACS Dissociator.
2.4. Immunohistochemistry
Paraffin-embedded sections (5 µm) were used for IHC staining with Tyramide Signal
Amplification (PerkinElmer, USA). The following primary antibodies were used: rat antimouse CD3 (CD3-12), rabbit anti-mouse CD4 (EPR19514), rat anti-mouse CD8a (4SM15),
rat anti-mouse Foxp3 (FJK-16S), rabbit anti-mouse PD1 (EPR20665).
The immune cell counts per square millimeter were averaged across replicates. The
cut-off values of low versus high immune cells were defined by the midpoint. The slides
were examined with a Keyence BZ-X810 microscope using Camera Software BZ-H4A
(Keyence Corporation of America, Raleigh, NC, USA). The density of TILs calculation was
as follows:
Density of TIL = cells count number/size of image field of view (mm2 )
Image field of view (height, width, diagonal) = (CCD sensor size (height, width,
diagonal))/(objective magnification x adapter magnification).
2.5. Cytolytic Activity
Cytolytic T-cell activity was determined by a cell-based flow cytometry assay. As
previously described [4], syngeneic B16F10 target cells were labeled with 1 µM carboxyfluorescein succinimidyl ester (CFSE, Biolegend). The purified splenocytes were the effecter
cells. Effecter cells (1 × 106 ) were cultured with CFSE-labeled target B16F10 cells (5 × 104 ).
Then, 4 h after incubation, propidium iodide (PI, 1 µg/mL, Sigma-Aldrich, MO) or 40 ,6-
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Diamidino-2-phenylindole dihydrochloride (DAPI, 1 mg/mL, Sigma-Aldrich) was added.
The cytotoxic activity was measured by flow cytometric analysis comparing CFSE+ PI+ or
CFSE+ DAPI+ cells with CFSE+ PI− or CFSE+ DAPI− cells. The percentage of specific lysis
(cell/CFSE+ PI+ ) was calculated as follows:
%Specific lysis = 100 × (%sample lysis − %basal lysis)/(1 − %basal lysis)
2.6. ELISA
The expression of IL-12 and IFN-γ in tumor tissue and plasma was determined using
the corresponding ELISA analysis kits from eBioscience (ThermoFisher, Waltham, MA,
USA) and R&D Systems (Minneapolis, MN, USA).
2.7. Flow Cytometry
The following monoclonal antibodies (mAbs) were used: anti-CD3 (PE vio770, REA
641), anti-CD4 (vioBlue, REA 604), anti-CD8a (APC-vio770, 53-6.7), anti-CD25 (APC, REA
568), anti-CD127 (FITC, A7R34), anti-PD1 (PE, REA 802), anti-NK1.1 (PE, PK136), antiCD11b (APC, REA 596), anti-Gr-1 (vioBlue, RB6-8C5), anti-CD45 (PerCP vio 700, REA737),
anti-CD44 (FITC, REA 664), anti-CD62L (APC, REA 828). The above antibodies were
purchased from Miltenyi (Miltenyi Biotech). Anti-NKp46 (FITC, 29A1.4), anti-H-2Kb (APC,
AF6-88.5), and anti-PDL1 (PE, 10F.9G2) were purchased from BioLegend and analyzed
using MACSquant analyzer 10 (Miltenyi, Bergisch Gladbach, Germany). FlowJo software
V10 (Tree Star, Inc., USA) was performed analysis using.
2.8. Statistical Analysis
One-way ANOVA was used to compare results from more than two treatment groups.
The statistical significance of differences in survival curves was determined by log-rank
survival analysis. All of the quantified data are presented as mean ± standard deviation
(SD). Statistical analyses were performed with commercially available software (SPSS
16.0 and GraphPad Prism 5, San Diego, CA, USA), and p values < 0.05 were considered
statistically significant.
3. Results
3.1. Tumor Regression by Combination Therapy
Given the high expression of PD1 on TILs (Supplementary Figure S1A–C), we evaluated whether pIL-12 GET in combination with anti-PD1 could induce a robust anti-tumor
immune response. We investigated the anti-tumor activity of pIL-12 GET and the combination of pIL-12 GET with anti-PD1 in the setting of intraperitoneal metastatic B16F10
melanoma (Figure 1A). pIL-12 GET showed impressive attenuation of the primary tumor
(s.c.) growth (Figure 1B); however, there was a weak anti-tumor response against the
intraperitoneal metastatic tumor (Figure 1C,D). Though the anti-PD1 group demonstrated
a response in intraperitoneal metastatic growth, there was not an observed response on
the subcutaneous tumor (Figure 1B–D). Compared to pIL-12 GET or anti-PD1 alone, the
combination treatment (pIL-12 GET+anti-PD1) improved tumor control, which inhibited
both the primary and intraperitoneal tumor progression (Figure 1B). A dramatic reduction
in the IVIS signal of intraperitoneal metastases was observed with the combination treatment (Figure 1C–E). Greater than 80–90% of mice treated with the combination achieved
long-term survival (Figure 1E). Without GET, the pIL-12 treatment (injection only) showed
a weak anti-tumor effect, even when combined with anti-PD1 (Figure 1), which is consistent
with previous results [4]. Mice whose primary tumors received pIL12 GET had not only
the treated tumor regress but also induced attenuation of tumor growth in distant lesions
mediated indirectly by IL-12 priming in treated tumors. Anti-tumor effects seen in distant
contralateral lesions are, therefore, likely mediated by changes in tumor immunity generated in the treated tumors. The combination of pIL-12 GET and anti-PD1 immunotherapy
further enhanced survival compared to pIL-12 GET alone and led to long-term tumor
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3.3. Endogenous IFN-γ Response within Tumors with pIL-12 GET Combination Treatment
The TME was evaluated to determine key aspects of pIL-12 GET and combination
treatment related to therapeutic outcomes, particularly the abundance of infiltrating T cells
in tumor tissue (Figure 2C) and levels of IFN-γ and IL-12 within the TME. IFN-γ and IL-12
were significantly induced following combination therapy, and pIL-12 GET monotreatment
when compared to the no TX group (Figure 3A,B). Achieving similar levels of IFN-γ and
IL-12 following combination therapy and pIL-12 GET monotreatment was not surprising as
each group received the same intratumor treatment; however, these data demonstrates that
the addition of anti-PD-1 did not adversely affect the activity of pIL-12 GET. Intratumoral
cytokine levels increased on day 4 and remained elevated out to day 8, which was the last
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day that intratumoral levels could be assessed. As shown in Figure 1B, with treatment,
6 of 20
the tumor volume shrank from around 50 mm3 to around 10 mm3 , at which point it was
difficult to obtain tumor homogenate.
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Thus, combination therapy elicited substantial remodeling of the TME with contributions
from CD4+ and CD8+ T cells, particularly the latter.
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Although
the Notably,
and CD8 PD1 T cells were infrequent in combination therapy (Figure
3I–K).
+ T cells were dispensable for pIL-12 GET combination therapeutic efficacy, we found
CD4
pIL-12 GET and combination therapy induced tumor infiltration by effector CD4+ and
that the
+ combination anti-tumor effect predominantly relied on CD8+ T cells (Figure+4D,E). +

CD8 T cells (Figure 3J,K). Interestingly, we found the frequency of CD4 Foxp3 T cells
in both pIL-12 GET and combination group to be lower than that of the control groups
(Figure 3L) and the ratio of CD8+ PD1− to CD4+ Foxp3+ to be higher (Figure 3M). The cells
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expressing the exhaustion marker PD-1 in peripheral blood and spleen were detected with
flow cytometry (Figure S3F–I)
The analysis of the IHC results indicated that there were peri-tumoral lymphocytic
aggregates with prominent perivascular localization and intra-tumoral lymphocytic penetration in the combination and monotherapy groups as opposed to the no TX group
(Figure S4A). Together, these data indicated that T cells infiltrated into the TME in an IL-12dependent manner, and anti-PD1 immune checkpoint blockade decreased the number of
exhausted T cells.
3.5. CD8–CD4- and IFN-γ-Dependent Manner of Anti-Tumor Efficacy
To further delineate the contribution of the host immune response to the anti-tumor
effect of combination therapy, we treated tumor-bearing mice with depleting anti-CD4,
CD8, NK1.1, or IFN-γ antibodies to eliminate, respectively, CD8+ T cells (Figure 4A,B),
CD4+ T cells (Figure 4C,D), NK cells (Figure 4E,F), and IFN-γ (Figure 4G,H). Although
the CD4+ T cells were dispensable for pIL-12 GET combination therapeutic
efficacy, we
Pharmaceutics 2022, 14, x FOR PEER REVIEW
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3.6. Augmentation of Killing Capability in T Cells
Given that the principal aim of this study was to use the pIL-12 GET combination
with anti-PD1 for generating robust functional T-cells (CD8+ PD1−), we tested the capacity
of the expanded cytotoxic T-cells to kill targeted cancer cells. Using CFSE-stained B16F10
at a 10:1 or 20:1 effector-target ratio, there was around 1.5-fold augmentation in the
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and combination treatment was prolonged.
To further characterize the cytotoxicity of dominant cells, we sorted CD4+ and CD8+
T cells from the spleen of tumor-free mice on day 56 and examined the cytotoxic capacity
of these two cell types with flow cytometry. Compared to sorted CD4+ T cells, sorted CD8+
T cells displayed a higher effect on target B16F10 cells (Figure S4B).
To better understand the immunomodulatory effects of pIL-12 GET and the9 of 18
associated mechanism of action in metastatic B16F10, we quantified the key killing
mediators granzyme B and IFN-γ. As shown in Figure 5H–J, the CD8+ T-cells displayed a
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Figure 5. Combination therapy elicits T cells responses and is maintained for a long-term duration.
On day 8, 36, 56, and 111, spleens were isolated from the mice (n = 5/group/experiment). After
preparing single cells, splenocytes were cocultured at different ratios with CFSE-labeled B16F10 cell
targets for 6 h. The cytotoxic activity of T cells was analyzed with FACS. (A,B) Representative FACS
analysis of cytotoxicity of T cells. (C–E) Quantification of DAPI+/CFSE+ of the target population in
comparison to the control population (CFSE-labeled B16F10 cells group). (F,G) Representative dot
plots showing the gating strategy for granzyme B and IFN-γ. (H–J) Kinetics of IFN-γ or granzyme B
production by CD8 and CD4 cells during days 8–111 after the onset of treatment. The experiments
were performed three times, yielding similar results. * p < 0.05, *** p < 0.001.

To further characterize the cytotoxicity of dominant cells, we sorted CD4+ and CD8+ T
cells from the spleen of tumor-free mice on day 56 and examined the cytotoxic capacity of

Pharmaceutics 2022, 14, 2429

10 of 18

these two cell types with flow cytometry. Compared to sorted CD4+ T cells, sorted CD8+ T
cells displayed a higher effect on target B16F10 cells (Figure S4B).
To better understand the immunomodulatory effects of pIL-12 GET and the associated mechanism of action in metastatic B16F10, we quantified the key killing mediators
granzyme B and IFN-γ. As shown in Figure 5H–J, the CD8+ T-cells displayed a higher level
of IFN-γ and granzyme B compared with CD4+ T cells. Surprisingly, there was no apparent
difference in the level of expression of granzyme B on days 8 and 111 (Figure 5H,J). Notably,
on day 36, the highest production of IFN-γ and granzyme B was consistent with the more
robust cytotoxic ability of the target cells (Figure 5D,I). Splenic CD8+ T cells harvested from
either no TX group or pIL-12 GET treatment group, these cells were capable of producing
the key effector cytokines IFN-γ and granzyme B (Figure 5H–J), the splenic CD8+ T cells
from tumor-bearing mice induced higher IFN-γ production from day 8 compared to CD4+
T cells (Figure 5H). The production of IFN-γ from CD8+ T cells was up to the peak on day
36 (Figure 5I) and followed by a decrease on day 111 in the pIL-12 GET and combination
treatment group (Figure 5J). However, the tumor was eliminated after day 36. Interestingly,
the granzyme B production from CD8+ T cells was higher than from CD4+ T cells on day 36.
These results demonstrate that T-cell behavior in vitro might not accurately predict their
activation and function in the tumor context.
3.7. Mediating Long-Term Tumor Protection
To determine whether pIL-12 GET and combination therapy could elicit durable
tumor-specific T-cell responses, we rechallenged the long-term surviving mice (>50 days).
Using naive mice as controls, all of the surviving mice were rechallenged with injections
of 5 × 105 B16F10 tumor cells in the right flank on Day 50. One hundred percent of
the naive mice developed tumors 7 days after the rechallenge. Compared to the naïve
mice, a majority of the surviving mice exhibited complete protection (Figure 6A,B). This
survival pattern indicated that the surviving mice have long-term immunologic memory
against B16F10 cells, and this protection depended on memory T cells. The central memory
(CD44+ CD62L+ ) and effector memory (CD44+ CD62L− ) was identified by flow cytometry
(Figure 6C–F). Nonetheless, these results showed that a predominant amount of protective
immunity afforded by pIL-12 GET and combination with anti-PD1 is driven by CD4+
and CD8+ T cells, and this protection can be enhanced by antigen boost, at which the
increased percentage of the effector memory and central memory CD4+ and CD8+ T cells
after rechallenge (Figure 6C,E; 50 days post rechallenge). To further explore the immune
system balance, we detected CD3+ PD1+ T cells, Treg (CD3+ , CD4+ , CD25+ , and CD127− ),
and myeloid-derived suppressor cells (MDSCs, CD11b+ Gr-1+ ) as well (Figure 6G).
3.8. pIL-12 GET Derived-Tumor Immune Modulatory Program
A slight growth delay in the vector GET group was observed in the empty vectortreated mice as compared with the untreated mice (Figure 7A). With respect to immune
escape strategies aimed to avoid T-cell recognition, including the loss of tumor MHC
class I expression, which has proven to have a negative effect on the clinical outcome of
cancer immunotherapy, including treatment with antibodies blocking immune checkpoint
molecules, we detected the major histocompatibility complex class I (MHC-I) surface
expression on tumor cells from melanoma tumor tissue (H-2Kb). We show that MHC-I was
upregulated in B16F10 tumor-bearing mice treated with vector GET and pIL-12 GET.
One role of IL-12 is to recruit and activate NK cells and T cells, which then release
IFN-γ [28–30]. Therefore, we next sought to determine whether IFN-γ exhibited immunemodulatory functions in the context of B16F10 tumors, such as the decreased expression
of a negative immune regulatory factor or the increased expression of positive immune
markers. The B16F10 cells were co-cultured with various doses of IFN-γ for 24, 48, and
72 h in culture, followed by flow cytometry analysis. This resulted in dramatically higher
expression of H-2Kb and PDL1 in a dose-dependent response but was time-independent
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3.8. pIL-12 GET Derived-Tumor Immune Modulatory Program
A slight growth delay in the vector GET group was observed in the empty vectortreated mice as compared with the untreated mice (Figure 7A). With respect to immune
escape strategies aimed to avoid T-cell recognition, including the loss of tumor MHC class
I expression, which has proven to have a negative effect on the clinical outcome of cancer
immunotherapy, including treatment with antibodies blocking immune checkpoint
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These data strongly suggested that IFN-γ and plasmid vector pUMVC3 (data not shown),
which was used in the current study, increased the expression of H-2Kb and PDL1on
B16F10 cells. Thus, the immunomodulatory effects of pIL-12 GET likely involve the
upregulation of class-I antigen presentation to potentiate CD8+ T cell responses. These
strategies may be useful to potentiate anti-tumor immunity and responses to checkpoint
12 of 18
inhibition in immune-refractory melanoma cancers.
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and the single cells were prepared for flow cytometry testing H-2Kb and PDL1 surface expression
isolated, and the single cells were prepared for flow cytometry testing H-2Kb and PDL1 surface
expression on B16F10. (C). B16F10 cells were seeded into 6-well plate after treatment with electric
pulses in the presence of recombination of mouse IL-12 (IFN-γ group as positive control) and grown
for 24 h. After that, the expression of H-2Kb and PDL1 were assessed by flow cytometry (D,E). Flow
cytometry data of H-2Kb and PDL1 surface expression on B16F10 cells in different treatments. After
treating with electric pulses, B16F10 cells were seeded into 6-well plate for 24 h culture in 6-well plate.
* p < 0.05, ** p < 0.01.

To confirm that the agents upregulating the expression of MHC-I was not from IL-12
encoded by pIL-12, we incubated the B16F10 cells with different concentrations of mouse
IL-12. As shown in Figure 7C, there was a weak effect of IL-12 and pulse only on H-2Kb
and PDL1 expression. To further investigate the function of pIL-12 GET on the expression
of MHC-I and PDL1, we performed in vitro tests. pIL-12 GET enhanced H-2Kb and PDL1
expression on B16F10 cells (Figure 7D,E). Obviously, there was a synergy between plasmid
IL-12 GET and IFN-γ, and there are more complex effectors that influenced the expression
of H-2Kb and PDL1 on B16F10 melanoma in TME.
Previous studies have shown that IFN-γ signaling is triggered after engagement to the
heterodimeric receptor of IFN-γ (IFN-γR), which is ubiquitously expressed on virtually
all normal cell surfaces [31]. We next measured the IFN-γR expression on B16F10 cells
with flow cytometry. We found no evidence for inhibitory or stimulatory effects of IL-12,
pIL12 GET, and IFN-γ-treated B16F10 cells on IFN-γR expression (data not shown). These
data strongly suggested that IFN-γ and plasmid vector pUMVC3 (data not shown), which
was used in the current study, increased the expression of H-2Kb and PDL1on B16F10
cells. Thus, the immunomodulatory effects of pIL-12 GET likely involve the upregulation
of class-I antigen presentation to potentiate CD8+ T cell responses. These strategies may
be useful to potentiate anti-tumor immunity and responses to checkpoint inhibition in
immune-refractory melanoma cancers.
4. Discussion
A successful anti-tumor immune response requires a few key steps: (a) the capture
of tumor antigens by MHC molecules, which are expressed on antigen-presenting cells
(APCs), (b) the activation and expansion of CD4+ and/or CD8+ T cells, (c) the production
of inflammatory cytokines (i.e., IFN-γ), and cytotoxin (i.e., granzymes B, perforin). The
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status of the tumor microenvironment has a great deal of influence on the effectiveness of
immunotherapy approaches. A cold, altered, or immunosuppressed microenvironment
that has low levels of lymphocytic infiltrate or an immunosuppressive environment can
negate many immunotherapeutic approaches. This type of environment has led to clinical
benefit being elusive for most patients with cancer, resulting in low response rates and a
lack of complete responses. The insufficient number of highly functional immune effector
cells in the tumor microenvironment (TME) is one of the key elements. Modifying the
environment to be hot where there is an increased infiltrate of activated T cells and/or
increased expression of checkpoints can make the tumor(s) more responsive to certain
immunotherapeutic approaches [32–35].
The intratumoral administration of plasmid IL-12 provides a critical bridge between
innate and adaptive immunity to meet the above requirements by recruiting and activating
natural killer (NK), NKT, and CD4+ and/or CD8+ T cells into the tumor microenvironment
with less toxicity. There is thus an unmet clinical need for therapeutic strategies to convert
the TME to an effective functionally inflamed immune landscape able to promote and
sustain significant clinical benefit [35–38].
The observations of the activated antigen-directed TILs in the tumor milieu were associated with favorable prognosis in cancer patients [39–42]. Immune checkpoint inhibitors
have been approved based on durable efficacy [7,8]. However, despite these promising
long-term clinical responses, the majority of patients fail to respond to immune checkpoint
inhibitors, demonstrating primary or acquired resistance [43–46]. Thus, there is an urgent
need to improve its efficacy and reduce resistance.
Electroporation, with high intensity and short duration, has been used in vivo to
permeabilize the plasma membrane of cells for the delivery of plasmid DNA and cytotoxic
agents. We have previously demonstrated that by modifying the electrotransfer pulse
parameters, an expression pattern for the delivered transgene can be obtained that can
lead to the desired therapeutic outcome [47]. Due to its safety, efficacy, flexibility, ease
of application, and low cost, gene electrotransfer is becoming popular in clinical trials.
Currently, there are over 100 clinical trials (ClinicalTrials.gov) using electroporation to
deliver plasmid DNA. Therefore, localized pIL12 GET may be best realized in combination
with immune checkpoint inhibitors [48–54].
Based on the previous results, without GET, pIL-12 injection only results in very low
levels of expression and induces a weak anti-tumor effect [4,47,49]. One of the major
obstacles in non-viral gene delivery is the interstitial transport of large nucleic acids and
their carriers (such as plasmid DNA). Genes must first gain access to the cell surface before
they are able to enter cells and achieve protein expression. Plasmid DNA can be introduced
into cells using electric pulses. In order to obtain controllable expression of IL-12, we have
optimized the parameters of electroporation to attenuate tumor growth [55].
Dependent on the goals of the gene transfer approach, gene therapy can be performed
to achieve two different delivery results: transient gene expression and stable transfection.
The main discrepancy between transient and stable transfection is that during transient
transfection, the gene of interest fails to integrate with the host genome and is expressed
temporarily within the host for a short term, whereas, in a stable transfection, the gene of
interest integrates with the host genome and is sustained long term for several generations.
With respect to the main purpose of pIL-12 GET, we performed transient gene expression as
we did not want to have a high or long expression of pIL-12, which could lead to toxicity as
well as induce immunosuppression instead of immunostimulation. Furthermore, transient
gene expression avoids the high risk of carcinogenic mutation after genomic integration.
Gene electrotransfer with IL-12 is an effective anti-tumor treatment already used in
preclinical and clinical oncology [30,56–59]. A key driver in amplifying this local therapy
into a systemic response is the magnitude and composition of immune infiltrate in the
treated tumor. While intratumoral IL-12 typically increases the density of CD3+ T cells,
this infiltrate is educated by the tumor milieu into exhausted T cells. To encourage a more
favorable on-treatment tumor microenvironment, we explored combining pIL-12 GET with
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anti-PD-1 to productively engage a diverse subset of lymphocytes. This therapy yielded
high ratios of CD8+ /PD1− cells in the tumor and decreased the numbers of Tregs, creating
a tumor microenvironment conducive to the influx of CD8+ T cells. The infiltration of
highly active CD8+ /PD1− T cells was associated with tumor remission and significantly
extended survival in tumor-bearing mice. More importantly, long-term tumor-free mice
were resistant to tumor growth following subsequent tumor rechallenge and were shown
to have induction of long-term tumor antigen-specific immunological memory. These
observations are critical to establishing a therapeutic approach that can prevent regrowth
or treat metastatic disease [54,60–62]. Survival studies in our peritoneal metastatic tumor
model showed a marked decrease in mortality among mice with combination treatment vs.
pIL-12 GET alone or anti-PD1 inhibitor alone. There were overlapping effects of IL12-GET
and combination therapy in the primary subcutaneous tumor.
Durable anti-tumor immune protection can be defined as a subset of persistent antigenspecific memory T cells, which could mediate and coordinate a faster, stronger, and more
prolonged response to tumor antigen re-encounter. In the current study, the induction
of persistent tumor immunity by pIL-12 GET combined with anti-PD1 in tumor-bearing
mice was supported by (a) successful resistance to tumor cells rechallenge, (b) improved
levels of antigen-specific cytotoxic T lymphocytes responses in vitro, (c) elevation in the
total numbers of CD4 and CD8 T cell populations in the tumor milieu, (d) raised number
of activated/memory CD8+ T cell subpopulations in the spleens of treated mice. These
results suggest that pIL-12 GET combined with anti-PD1 worked to maintain memory
and/or activated T cells, initiated and potentially modulated host anti-tumor immune
responses in mouse models with primary subcutaneous tumor and peritoneal metastases
simultaneously. Subsequently, the release by electric pulse-induced cellular manipulation and re-expressed tumor-associated antigens by host antigen-presenting cells may
aid, in part, the generation and maintenance of memory T cells [63–66]. While the full
mechanism of immunologic memory remains unknown, it has been suggested that the
successful generation of long-lived memory T cells is dependent on several factors, including the cytokines in the tumor microenvironment [66]. Therefore, we assessed the
role of pIL-12 GET combined with an anti-PD1 inhibitor in recruiting and activating the
lymphocytes, which may play a crucial role in mediating tumor regression and establishing
long-term immunity.
Immune-escape strategies of tumor cells aimed to avoid T-cell recognition, including
the loss of tumor MHC class I expression, are commonly found in malignant cells [21,24].
Studies have shown that the upregulated expression of MHC class I molecules, led to
more efficient processing and presentation of MHC class I-associated peptides at the cell
surface in a variety of cells including different types of tumors [67,68]. It is clear that IL-12
induced cell-derived IFN-γ therapy and local secretion of IFN-γ at the tumor site plays
an important role in increasing MHC class I expression. However, in the current context,
pIL-12 GET converted the tumor cells into “antigen-presenting cells”, which heightened
the opportunity of T cell activation. Interestingly, the data from in vitro studies indicated
that plasmid vector pUMVC3 has the capability of increasing the MHC class I surface
expression on tumor cells (data not shown) as well. The mechanisms of plasmid vector
pUMVC3 upregulation of MHC class I surface expression on tumor cells requires further
study to fully understand.
In addition, the increased PDL1 expression on tumor cells is also important to monitor
(Figure 7). Evidence from clinical cases indicated that response rates to immune checkpoint
blockade range from 36% to 100% for PDL1-positive tumors, while patients whose tumors
do not express PDL1 can experience a response rate ranging from 0% to 17% [69–71]. The
results from our lab found that PDL1 is an inducible and highly dynamic ligand that
can change over time (data not shown). Importantly, IFN-γ can induce the production
of PDL1 in cancer cells [72–75]. In the study reported here, the induction of PDL1 by
IFN-γ did not overwhelm the anti-tumor effects of IFN-γ, which is partly consistent with
previous findings [76]. Notably, we also found that plasmid vector pUMVC3 could increase
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the PDL1 surface expression on B16F10 tumor cells. Given that the efficacy of immune
checkpoint inhibitors depends on the activated T cells in the tumor milieu, which is modulated by chemokine/chemokine receptor interaction [77,78], this prompted us to evaluate
chemokine networks.
In summary, we showed that pIL-12 GET alters the tumor microenvironment from
the suppressive condition to an anti-tumor milieu. These data highlight CD44+ T memory
cells in circulation as more representative of cells at immune sites and underscore the
importance of evaluating the peripheral blood when making determinations about immune
surveillance being able to successfully prevent tumor relapse and metastasis. More broadly
speaking, these findings may guide the development of combination cancer therapies to
make tumors more accessible for targeted immune therapy and vaccination to establish
long-term anti-tumor immunity in patients.
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